association remains unclear, especially because of the nonrandomized nature of the published studies. 1-4 A nonexhaustive list of hypotheses includes delays in treatment, risks related to intubation, hemodynamic changes, or specific effects of anesthetic drugs that could interfere with in situ fibrinolytic agents. 5 Until prospective, randomized studies that address the effect of anesthetic agents in acute ischemic stroke are undertaken, we suggest that trials that evaluate endovascular strategies should standardize and report the regimens of these agents to allow secondary analyses. Clement Gakuba, M.D.
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To the Editor: Two of the reasons for the failure to prove the efficacy of endovascular treatment in these three randomized trials are the use of first-generation devices and the delayed (in the studies by Broderick et al. and Ciccone et al.) or absent (in the study by Kidwell et al.) introduction of new techniques in the study protocols. Recent randomized studies have clearly shown that stent retrievers were more efficacious than the Merci device. 1,2 Stent retrievers were used in 4 patients in the IMS III trial and in 23 patients in the SYNTHESIS Expansion trial; they were not allowed in MR RESCUE.
Furthermore, the large proportion of patients in whom there was a very long time from the start of intravenous thrombolysis to groin puncture indicates that the best clinical pathways were not used in several study sites. In addition, cross-sectional angiography before random assignment of patients to intravenous or interventional treatment should be mandatory.
In To the Editor: Kidwell et al. completed a rigorous, randomized evaluation of imaging-based treatment selection. However, their conclusion that penumbral-imaging selection did not identify a subpopulation of patients who would have a favorable response to endovascular therapy for stroke conflicts with previous findings. 1-3 The MR RESCUE trial did show significantly better outcomes in patients with a favorable penumbral pattern when recanalization occurred; these findings were consistent with those of previous studies, despite relatively large infarcts at baseline and a complex "penumbral selection" method. Interpretation of these data and the apparent response to recanalization in the nonpenumbral group is hampered by a lack of reported baseline characteristics for these subgroups. In addition, the key cofactors of reperfusion and recanaliza- Stephen M. Davis, M.D.
University of Melbourne Parkville, VIC, Australia
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To the Editor: Broderick et al. and Ciccone et al. described studies comparing intravenous tissue plasminogen activator (t-PA) alone with intravenous t-PA plus endovascular treatment for acute ischemic stroke, and they found no advantage with endovascular treatment. These studies include patients with both large and small distalvessel occlusions who probably benefit from different treatment approaches. Stent-based thrombectomy, the state-of-the-art endovascular approach, was used in only a handful of patients. Because of these limitations, both studies should be viewed with caution.
Intravenous t-PA improves outcomes in patients with mild-to-moderate stroke by recanalizing small-to-midsize arteries; however, its efficacy in recanalizing major large-vessel strokes is limited. Outcomes with early endovascular techniques -intraarterial thrombolysis and mechanical thrombectomy -were limited by long procedure times.
The newest stent-based thrombectomy devices allow unprecedented rapid complete recanalization rates (Thrombolysis in Myocardial Infarction risk score, 3 on a scale of 0 to 3, with 0 indicating no flow and 3 normal flow; TICI score, 2b to 3) in occlusions of the proximal middle cerebral artery. We found that stent-based thrombectomy provides superior outcomes as compared with intravenous t-PA in these patients, 1 with good functional outcome (a score of 0 to 2 on the modified Rankin scale, which ranges from 0 to 6, with higher scores indicating greater disability) in the majority of patients. 2 The SWIFT study also showed superior results with current devices as compared with the Merci device. technology for clot removal during the course of the trial, which did occur. Unfortunately, our trial was halted prematurely for futility after only a handful of patients had been treated with the trial-approved Solitaire stent-retriever device, and we agree that the trial cannot address the efficacy and safety of the devices. However, many interventionalists did not participate in our study because they believed that the older endovascular approaches were superior to intravenous t-PA alone, which the trial did not show. Randomized trials of the new endovascular technology as compared with intravenous t-PA alone, including SWIFT PRIME and Assess the Penumbra System in the Treatment of Acute Stroke (THERAPY; NCT01429350), are ongoing. We agree with the importance of vascular imaging before treatment in clinical trials of endovascular therapy. When our study began in 2006, few centers used computed tomographic (CT) angiography as part of the standard evaluation of patients with acute stroke. 1 For this reason, we used a score of 10 or more on the National Institutes of Health Stroke Scale (ranging from 0 [no neurologic deficit] to 42 [maximum possible deficit]) to identify patients with a high likelihood of an intracranial artery occlusion on angiography after intravenous t-PA. The use of CT angiography as a diagnostic tool dramatically increased during the trial, and we incorporated its use so that nearly half the trial patients underwent vascular imaging before treatment. In a prespecified analysis, we found no significant difference in outcomes in patients with a pretreatment occlusion of the internal carotid artery, proximal middle cerebral artery, or basilar artery.
Our study, which included many of the most experienced sites in the world with regard to endovascular therapy, emphasized rapid therapy in its design, but it still had a longer time to the start of endovascular therapy than the smaller, single-group IMS I 2 and II 3 trials. We agree that minimization of the time to the start of endovascular therapy will be critical to show its efficacy, and we recommend critical examination of the delivery of stroke care in the United States, in which patients are commonly treated with intravenous t-PA at a community hospital and then are transported to a tertiary center for additional endovascular therapy.
We agree with Gakuba and colleagues about the role of general anesthesia in endovascular therapy. Drs. Ciccone and Valvassori Reply: We were glad to contribute to the evidence on the efficacy of endovascular treatment for stroke. The SYNTHESIS Expansion investigators have worked with great enthusiasm, even though the results were different from what was expected. We expected to confirm the common perception of the superiority of endovascular treatment over intravenous t-PA. Our findings confirm the importance of conducting randomized, controlled trials in this area. The comparative trials of old-and new-generation retrievers for thrombectomy revascularization (Trevo vs. Merci and Solitaire vs. Merci) described by Arnold et al. favor this erroneous perception. If endovascular therapy is intended to be stent-based thrombectomy with devices such as Trevo and Solitaire, then the first step in showing the efficacy of endovascular therapy, in our view, would be to show, with a well-designed, randomized, controlled trial, that stent retrievers are superior to intravenous t-PA in patients with large-vessel stroke. Unfortunately, the studies cited by Cohen and Leker which favored thrombectomy were not randomized, controlled trials and as such have many types of bias, as described by Mullen et al. in their systematic review. 1 The investigators in our trial aimed to produce evidence that would support the diffusion of endovascular treatment to reduce the stroke burden nationwide, not in a subgroup of patients with ischemic stroke. We were not interested in a specific device; our study pragmatically allowed the use of the devices that were available on the market at the time of the study and, inevitably, its results are related to the devices available when it was conducted. The invitation by Gakuba et al. to perform a subgroup analysis involving patients who received anesthesia should be considered with caution: different institutions have different treatment protocols that are not always related to the clinical status of the patients. In some centers, patients in critical condition are more likely to undergo intubation; thus, bias is introduced in the analyses.
The same difficulties could be encountered in evaluating the subgroup of patients in whom stent retrievers were used in our trial: they were used mostly in the last part of the trial and only in a few centers. Even if the results seem slightly more encouraging in this subgroup, the numbers are definitely too small to draw conclusions.
Overall, we are in agreement with the accompanying editorial by Chimowitz, and we think that these three trials are not the end of trials of endovascular therapy but are rather a stimulus for new randomized, controlled trials of the use of the endovascular approach. Since publication of their article, the authors report no further potential conflict of interest.
1. Mullen MT, Pisapia JM, Tilwa S, Messé SR, Stein SC. Systematic review of outcome after ischemic stroke due to anterior circulation occlusion treated with intravenous, intra-arterial, or combined intravenous+intra-arterial thrombolysis. Stroke 2012;43: 2350-5.
Dr. Kidwell and Colleagues Reply: With regard to recruitment and possible selection bias: the average recruitment rate per site was 1 patient every 8 months, since not all sites were active throughout the trial. There is as much, if not more, reason to be concerned about selection bias toward milder cases of stroke in other studies, including the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evaluation (DEFUSE 2) trial 1 and the study of tenecteplase reported by Parsons et al. 2 In the latter study, 2768 patients were screened and 75 were enrolled. The rate of good outcomes in the MR RESCUE trial cannot be directly compared with those of the IMS III and SYNTHESIS Expansion trials, which had shorter enrollment time windows and differing inclusion and exclusion criteria. We agree that the issue of generalizability for all imaging-based studies requires further scrutiny.
We agree with the concern raised regarding the potential effect of anesthesia management on outcome. We did collect information on anesthesia management in MR RESCUE, since there was reluctance from the endovascular community (endovascular surgeons, anesthesiologists, and interventional radiologists and neurologists) to adopt a single standard approach when our trial was conducted.
Our trial continuously updated the protocol to include newly available devices coincident with FDA clearances throughout the trial; stent retrievers entered practice only as enrollment was being completed. We concur that the results reflect the performance of first-generation neurothrombectomy technology.
With regard to the letter by Campbell et al.: we do not agree that our trial results conflict with previous findings. The Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) was a negative study that did not include a sufficient number of patients with a nonpenumbral pattern to test the imaging-selection hypothesis; therefore, no strong conclusions can be drawn from this study regarding penumbral-imaging selection. 3 Similarly, the DEFUSE 4 and DEFUSE 2 1 trials lacked control groups; no conclusions can be made definitively regarding the interaction of imaging selection and treatment for acute stroke versus control. We agree that early recanalization is likely to have the most benefit in patients with acute stroke.
In conclusion, as stated previously, we strongly endorse further randomized, controlled trials with new-generation devices to test both the efficacy of endovascular approaches to treatment for stroke and the full spectrum of the imagingselection hypothesis. We have substantial concerns about studies that select for enrollment a priori only patients with penumbra-imaging patterns. Without definitive proof of the hypothesis of penumbral-imaging selection, these studies could lead to misleading conclusions not only about imaging selection, but also about the criteria regarding which patients may benefit. Copyright © 2013 Massachusetts Medical Society. All rights reserved.
